This company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsAsensus Surgical（ASXC）株式概要医療機器メーカーであるアセンサス・サージカル社は、米国、欧州、中東、アフリカ、アジアにおいて、低侵襲手術（MIS）を強化する医療機器ロボットの研究・開発・販売を行っている。 詳細ASXC ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長2/6過去の実績0/6財務の健全性1/6配当金0/6報酬収益は年間52.08%増加すると予測されています リスク分析マイナスの株主資本 キャッシュランウェイが1年未満である 現在は利益が出ておらず、今後3年間で利益が出る見込みはない 過去1年間で株主の希薄化が進んだ +2 さらなるリスクすべてのリスクチェックを見るASXC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.3545.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-150m80m2016201920222025202620282031Revenue US$80.1mEarnings US$10.9mAdvancedSet Fair ValueView all narrativesAsensus Surgical, Inc. 競合他社Pro-DexSymbol: NasdaqCM:PDEXMarket cap: US$199.9mDIH Holding USSymbol: OTCPK:DHAIMarket cap: US$62.8kKORU Medical SystemsSymbol: NasdaqCM:KRMDMarket cap: US$190.2mSensus HealthcareSymbol: NasdaqCM:SRTSMarket cap: US$53.2m価格と性能株価の高値、安値、推移の概要Asensus Surgical過去の株価現在の株価US$0.3552週高値US$0.4052週安値US$0.17ベータ1.381ヶ月の変化2.66%3ヶ月変化44.36%1年変化23.54%3年間の変化-84.04%5年間の変化-97.12%IPOからの変化-98.34%最新ニュースお知らせ • Aug 23+ 2 more updatesAsensus Surgical, Inc.(NYSEAM:ASXC) dropped from S&P TMI IndexAsensus Surgical, Inc.(NYSEAM:ASXC) dropped from S&P TMI IndexNew Risk • Aug 15New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$11m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$57m free cash flow). Negative equity (-US$11m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$8.4m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Market cap is less than US$100m (US$76.3m market cap).お知らせ • Aug 08Asensus Surgical, Inc. to Report Q2, 2024 Results on Aug 13, 2024Asensus Surgical, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024お知らせ • Jul 23Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in UrologyAsensus Surgical, Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration or an expanded indication to treat adult and pediatric Urology patients with the Senhance® Surgical System. Healthcare providers perform upwards of 185,000 urological surgical procedures each year in the United States. While the Senhance System has been successfully utilized for Urology procedures outside the U.S. for several years, this expanded indication will open the door to this important specialty to leverage the advantages of the Senhance System in the U.S. patient population. The Senhance Surgical System is designed to increase surgeon control and reduce variability through Augmented Intelligence and deep learning capabilities.New Risk • Jun 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$61m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (US$63.9m market cap).Reported Earnings • May 16First quarter 2024 earnings: EPS and revenues miss analyst expectationsFirst quarter 2024 results: US$83.55 loss per share (further deteriorated from US$0.093 loss in 1Q 2023). Revenue: US$1.12m (up 15% from 1Q 2023). Net loss: US$22.5m (loss widened 1.3% from 1Q 2023). Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) also missed analyst estimates by 60%. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.最新情報をもっと見るRecent updatesお知らせ • Aug 23+ 2 more updatesAsensus Surgical, Inc.(NYSEAM:ASXC) dropped from S&P TMI IndexAsensus Surgical, Inc.(NYSEAM:ASXC) dropped from S&P TMI IndexNew Risk • Aug 15New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$11m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$57m free cash flow). Negative equity (-US$11m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$8.4m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Market cap is less than US$100m (US$76.3m market cap).お知らせ • Aug 08Asensus Surgical, Inc. to Report Q2, 2024 Results on Aug 13, 2024Asensus Surgical, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024お知らせ • Jul 23Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in UrologyAsensus Surgical, Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration or an expanded indication to treat adult and pediatric Urology patients with the Senhance® Surgical System. Healthcare providers perform upwards of 185,000 urological surgical procedures each year in the United States. While the Senhance System has been successfully utilized for Urology procedures outside the U.S. for several years, this expanded indication will open the door to this important specialty to leverage the advantages of the Senhance System in the U.S. patient population. The Senhance Surgical System is designed to increase surgeon control and reduce variability through Augmented Intelligence and deep learning capabilities.New Risk • Jun 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$61m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (US$63.9m market cap).Reported Earnings • May 16First quarter 2024 earnings: EPS and revenues miss analyst expectationsFirst quarter 2024 results: US$83.55 loss per share (further deteriorated from US$0.093 loss in 1Q 2023). Revenue: US$1.12m (up 15% from 1Q 2023). Net loss: US$22.5m (loss widened 1.3% from 1Q 2023). Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) also missed analyst estimates by 60%. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.Major Estimate Revision • May 16Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$12.3m to US$9.80m. Forecast losses increased from -US$0.185 to -US$0.27 per share. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$0.35 unchanged from last update. Share price was steady at US$0.26 over the past week.お知らせ • May 09Asensus Surgical, Inc. to Report Q1, 2024 Results on May 14, 2024Asensus Surgical, Inc. announced that they will report Q1, 2024 results After-Market on May 14, 2024New Risk • Apr 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$64m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$24m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (US$77.5m market cap).お知らせ • Apr 04KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million.KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million on March 28, 2024. As part of consideration, KARL STORZ SE & Co. will pay $0.35 in cash for each share of Asensus Surgical. If the proposed transaction is consummated, Asensus will cease to be a publicly traded company. The Bridge Loan will enable Asensus to receive a loan of up to $20 million from KARL STORZ to support the Company’s operations through the exclusivity period. The transaction is subject to, among other conditions, completion of due diligence by KARL STORZ, negotiation of a definitive merger agreement, a recommendation by the Transaction Committee and approval by the Board of Directors and stockholders of Asensus Surgical, and other customary closing conditions to be included in the definitive merger agreement, if any. If negotiations are terminated during the exclusivity period, or, if entered into, the definitive merger agreement is terminated, KARL STORZ will cease to provide any additional bridge financing and the Asensus Surgical will be required to repay the Bridge Loan to KARL STORZ within a prescribed period. Jefferies LLC acted as financial advisor to Asensus Surgical.Reported Earnings • Mar 22Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: US$0.31 loss per share. Revenue: US$8.58m (up 21% from FY 2022). Net loss: US$78.4m (loss widened 3.8% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.6%. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.お知らせ • Mar 16Asensus Surgical, Inc. to Report Q4, 2023 Results on Mar 21, 2024Asensus Surgical, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Mar 21, 2024Recent Insider Transactions Derivative • Feb 07President exercised options and sold US$131k worth of stockOn the 4th of February, Anthony Fernando exercised options to acquire 485k shares at no cost and sold these for an average price of US$0.27 per share. This trade did not impact their existing holding. For the year to December 2017, Anthony's total compensation was 18% salary and 82% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2023, Anthony has owned 1.49m shares directly. Company insiders have collectively bought US$38k more than they sold, via options and on-market transactions, in the last 12 months.Major Estimate Revision • Jan 20Consensus revenue estimates increase by 10%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$7.79m to US$8.59m. EPS estimate unchanged from -US$0.32 at last update. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target of US$2.00 unchanged from last update. Share price fell 9.9% to US$0.29 over the past week.お知らせ • Jan 08Asensus Surgical, Inc. Provides Unaudited Earnings Guidance for the Quarter and Full Year Ending on December 31, 2023Asensus Surgical, Inc. provided unaudited guidance For the quarter and full year ending on December 31, 2023. For the quarter, the company estimates preliminary unaudited revenue of approximately $5.1- $5.7 million. For the full year, preliminary unaudited 2023 revenue is expected to be approximately $8.2 - $8.8 million, representing revenues from the sale of three Senhance Systems, multiple system leases, and related revenues from instruments, accessories, and services.お知らせ • Jan 05Asensus Surgical, Inc. Develops the LUNA Surgical SystemAsensus Surgical, Inc. announced a key development milestone for LUNA, the Company’s second-generation surgical robotic system. During the week of December 11, 2023, the Company hosted a Surgeon Lab in Research Triangle Park, North Carolina to conduct an in vivo evaluation of LUNA’s hardware, software and instruments in porcine models. The lab allowed nine participating surgeons to evaluate the system's functionality through thirteen different procedures across gynecology, urology, and general surgery. LUNA, the Company’s Next Generation Digital Surgery Platform: LUNA is designed to elevate the standards of robotic-assisted surgery. The system integrates carefully crafted hardware and software architecture to prioritize safety, reliability, and performance. LUNA's features include a surgeon console with unconstrained handles, an interactive touchscreen, and an Ultra-HD 3D monitor. Additionally, the system boasts up to four independent robotic manipulator arms for procedural flexibility, alongside a unique instrument drive system supporting various advanced instrumentation options. LUNA is currently under development and has not been submitted to, or cleared by, the US FDA or other global regulators, and is not available for sale in any market.Reported Earnings • Nov 17Third quarter 2023 earnings: EPS in line with expectations, revenues disappointThird quarter 2023 results: US$0.072 loss per share (improved from US$0.08 loss in 3Q 2022). Revenue: US$1.09m (down 57% from 3Q 2022). Net loss: US$18.3m (loss narrowed 3.2% from 3Q 2022). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.お知らせ • Nov 08Asensus Surgical, Inc. to Report Q3, 2023 Results on Nov 14, 2023Asensus Surgical, Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023Reported Earnings • Aug 11Second quarter 2023 earnings: EPS misses analyst expectationsSecond quarter 2023 results: US$0.086 loss per share (further deteriorated from US$0.083 loss in 2Q 2022). Revenue: US$1.08m (up 8.8% from 2Q 2022). Net loss: US$20.7m (loss widened 5.3% from 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Aug 03Asensus Surgical, Inc. to Report Q2, 2023 Results on Aug 10, 2023Asensus Surgical, Inc. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$61m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$41m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$71.8m market cap).Major Estimate Revision • May 18Consensus EPS estimates fall by 23%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.26 to -US$0.32 per share. Revenue forecast of US$8.67m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$1.65 unchanged from last update. Share price fell 15% to US$0.58 over the past week.Reported Earnings • May 13First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.093 loss per share (further deteriorated from US$0.081 loss in 1Q 2022). Net loss: US$22.2m (loss widened 16% from 1Q 2022). Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 116% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Major Estimate Revision • Mar 09Consensus revenue estimates fall by 34%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$17.0m to US$11.2m. Forecast losses increased from -US$0.25 to -US$0.26 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$2.25 to US$1.75. Share price fell 2.3% to US$0.67 over the past week.Price Target Changed • Mar 06Price target decreased by 21% to US$1.75Down from US$2.22, the current price target is an average from 2 analysts. New target price is 159% above last closing price of US$0.68. Stock is up 9.5% over the past year. The company is forecast to post a net loss per share of US$0.26 next year compared to a net loss per share of US$0.32 last year.Reported Earnings • Mar 03Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: US$0.32 loss per share (further deteriorated from US$0.28 loss in FY 2021). Net loss: US$75.6m (loss widened 21% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.9%. Revenue is forecast to grow 69% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions Derivative • Feb 08President exercised options and sold US$406k worth of stockOn the 4th of February, Anthony Fernando exercised options to acquire 542k shares at no cost and sold these for an average price of US$0.75 per share. This trade did not impact their existing holding. For the year to December 2016, Anthony's total compensation was 6% salary and 94% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2022, Anthony has owned 823.12k shares directly. Company insiders have collectively sold US$253k more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Jan 10Asensus Surgical, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022Asensus Surgical, Inc. provided unaudited revenue guidance for the Fourth quarter and Full year 2022. For the quarter, the company expected unaudited revenue is to be approximately $2.2 million - $2.8 million. For the year, the company expected unaudited revenue is to be approximately $6.8 million - $7.4 million.Board Change • Dec 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. President, CEO & Director Anthony Fernando was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Major Estimate Revision • Nov 17Consensus revenue estimates fall by 17%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$9.15m to US$7.60m. Forecast losses increased from -US$0.31 to -US$0.32 per share. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$2.25 unchanged from last update. Share price rose 8.3% to US$0.44 over the past week.Reported Earnings • Nov 16Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.08 loss per share (further deteriorated from US$0.069 loss in 3Q 2021). Net loss: US$18.9m (loss widened 18% from 3Q 2021). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 12Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.08 loss per share (further deteriorated from US$0.069 loss in 3Q 2021). Net loss: US$18.9m (loss widened 18% from 3Q 2021). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.Price Target Changed • Nov 05Price target decreased to US$2.25Down from US$4.00, the current price target is an average from 2 analysts. New target price is 456% above last closing price of US$0.41. Stock is down 81% over the past year. The company is forecast to post a net loss per share of US$0.31 next year compared to a net loss per share of US$0.28 last year.お知らせ • Nov 01Asensus Surgical, Inc. to Report Q3, 2022 Results on Nov 10, 2022Asensus Surgical, Inc. announced that they will report Q3, 2022 results After-Market on Nov 10, 2022お知らせ • Aug 10Asensus Surgical, Inc. Announces Impairment Charges for Three Months Ended June 30, 2022Asensus Surgical, Inc. announced impairment charges for three months Ended June 30, 2022. For the period, the company announced Property and equipment impairment of $432,000.お知らせ • Jul 28Asensus Surgical, Inc. to Report Q2, 2022 Results on Aug 08, 2022Asensus Surgical, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2022お知らせ • Jun 29Asensus Surgical, Inc. to Showcase the Senhance Surgical System and Performance-Guided Surgery in Upcoming Society of Robotic and Digital Surgery ConferenceAsensus Surgical, Inc. announced the will be participating in the Society of Robotic and Digital Surgery Conference from June 30, 2022 until July 3, 2022 in Lake Buena Vista, Florida. Asensus Surgical's technology platform, Senhance® Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit (ISU™). The ISU enables machine vision-driven tools to gather data related to anatomical structures and control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field and allows a surgeon to change the visualized field of view using the movement of their instruments. As an organization, the Company’s goal is to revolutionize the way surgery is performed. The Company is helping to unlock clinical intelligence and capabilities to reduce surgical variability and the complications associated with it. Performance-Guided Surgery builds upon the foundation of Digital Laparoscopy by adding machine vision, augmented intelligence, and deep learning capabilities, and will be built upon the digital library of data collected from surgeries performed using Senhance. The insights gained from these cases will help deliver on the promise of consistently superior surgery regardless of a surgeon’s experience or skill level by guiding improved decision making, enriching collaboration, and enhancing predictability.お知らせ • Apr 26Asensus Surgical, Inc., Annual General Meeting, Jun 14, 2022Asensus Surgical, Inc., Annual General Meeting, Jun 14, 2022, at 11:00 US Eastern Standard Time. Agenda: To consider the election of the seven director nominees named in the attached proxy statement to serve as directors until the next annual meeting of stockholders and until their successors are elected and qualified; to consider an advisory vote to approve the compensation paid to the Company’s named executive officers for 2021; to consider ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022; and to consider the transaction of such other business as may lawfully come before the Annual Meeting or at any adjournment or postponement.お知らせ • Feb 24Asensus Surgical, Inc. to Report Q4, 2021 Results on Feb 28, 2022Asensus Surgical, Inc. announced that they will report Q4, 2021 results After-Market on Feb 28, 2022お知らせ • Sep 29Asensus Surgical, Inc. Announces Purchase of Senhance Robotic System by Loginov Moscow Clinical Scientific CenterAsensus Surgical, Inc. announced that Loginov Moscow Clinical Scientific Center, located in Moscow, Russia, has initiated its Senhance® Robotic Surgery program following the purchase of a Senhance Surgical System. The installation represents the first Senhance Surgical System to be used within Russia. Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3 mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit™ (ISU™). The ISU enables machine vision-driven control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field, and allows a surgeon to change the visualized field of view using the movement of their instruments. The newest ISU features expand upon these capabilities and introduce more advanced features including: 3D measurement, digital tagging, image enhancement, and enhanced camera control based on real-time data from anatomical structures while performing surgery. The Loginov Moscow Clinical Scientific Center (The Loginov MCSC) is one of the and most innovative institutions funded by the Moscow Health Department. The Loginov MCSC is a multi-disciplinary clinical, research, and training center hosting 48 medical departments, employing around 500 doctors, and performing more than 13,000 annual operations. The Loginov MCSC is headed by Professor Igor Khatkov, a proponent of minimally invasive surgical technologies and a world leader in laparoscopic pancreatic surgery. Since its founding in July 2013, The Loginov MCSC has spent considerable resources on educational activities. The training center trains specialists in 12 medical specialties in residency and four specialties in fellowship. The center features a program for the development of robotic surgery, headed by Professor Nikolay Matveev, carried out in cooperation with the Department of Surgery of the Biomedical Faculty, Pirogov Russian National Research Medical University.お知らせ • Sep 02Asensus Surgical Receives FDA 510(k) Clearance for Expansion of Machine Vision CapabilitiesAsensus Surgical, Inc. announced that it has received 510(k) clearance from the FDA for an expansion of machine vision capabilities on the previously cleared Intelligent Surgical Unit™ (ISU™). The ISU is utilized with the Company’s Senhance Surgical System which enables Digital Laparoscopy. The current features of the ISU enable machine vision-driven control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field, and allow a surgeon to change the visualized field of view using the movement of their instruments. The newest ISU features expand upon these capabilities and introduce more advanced features including: 3D measurement, digital tagging, image enhancement, and enhanced camera control based on real-time data from anatomical structures while performing surgery. This will be the first time any of these features will be clinically available in soft-tissue abdominal surgery. The 3D measurement feature enables the surgeon to use their instruments to designate points on the tissue floor to determine both straight-line distances as well as true topographic distances over the folds and recesses of the abdominal cavity. In traditional minimally invasive surgery, such measurements are estimated or require the use of a sterile measuring tape inside the abdominal cavity. Now 3D measurement allows for accurate readings to millimeter-level accuracy that can assist in various surgical tasks, such as the sizing of hernia mesh or the planning of a staple line. These measurement capabilities represent the first time surgeons have the ability to acquire accurate, real-time measurements without the need for additional tools.お知らせ • May 15Asensus Surgical, Inc. Expects to File for FDA 510(K) Clearance for the Next Wave of ISU Features During the Second Quarter of 2021 and Expects to Publish Clinical Papers in Peer Reviewed Journals on Health Economic Evidence Comparing Senhance, Robotics and Laparoscopy in General Surgery and GynecologyAsensus Surgical, Inc. announced that during the second quarter of 2021, the Company expects to achieve the following regulatory milestones: File for FDA 510(k) clearance for the next wave of ISU features. During the second half of 2021, the Company expects to publish clinical papers in peer reviewed journals on the following subjects: Health economic evidence comparing Senhance, robotics and laparoscopy in General Surgery and Gynecology.お知らせ • Mar 05Asensus Surgical, Inc. to Report Q4, 2020 Results on Mar 11, 2021Asensus Surgical, Inc. announced that they will report Q4, 2020 results After-Market on Mar 11, 2021お知らせ • Mar 04Asensus Surgical Announces FDA Clearance in General SurgeryAsensus Surgical, Inc. announced the company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States. Asensus Surgical's technology platform, Senhance® Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3 mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is intended to assist in the accurate control of laparoscopic instruments for visualization and endoscopic manipulation of tissue including grasping, cutting, blunt and sharp dissection, approximation, ligation, electrocautery, suturing, mobilization, and retraction. The Senhance Surgical System is intended for use in general laparoscopic surgical procedures and laparoscopic gynecological surgery. The system is indicated for adult use. It is intended for use by trained physicians in an operating room environment in accordance with the instructions for use.お知らせ • Jan 29TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $69.249999 million.TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $69.249999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 23,083,333 Price\Range: $3 Discount Per Security: $0.225お知らせ • Jan 15TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $31.25 million.TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $31.25 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: $1.25 Discount Per Security: $0.096875 Transaction Features: Registered Direct Offeringお知らせ • Dec 19TransEnterix, Inc. Announces Southern Surgical Hospital to Initiate a Senhance Digital Laparoscopic ProgramTransEnterix, Inc. announced that Southern Surgical Hospital has entered into an agreement to lease and utilize a Senhance Surgical System. The Senhance System is the first new abdominal robotic surgery platform to receive FDA clearance since 2000. It is the first and only digital laparoscopic surgical platform designed to maintain laparoscopic minimally invasive surgical standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including 3 mm microlaparoscopic instruments, eye-sensing camera control, and reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy. TransEnterix recently launched the first machine vision system in robotic surgery. This first-of-its-kind augmented intelligence capability is powered by the new Intelligent Surgical Unit on the Senhance Surgical System.お知らせ • Dec 18TransEnterix Announces Approval of Senhance Surgical System in Russian FederationTransEnterix, Inc. announced that the Senhance® Surgical System has received its registration certificate by Roszdravnadzor, the Russian medical device regulatory agency allowing for its sale and utilization throughout the Russian Federation.お知らせ • Nov 06+ 1 more updateTransenterix, Inc. Does Not Provide Forward-Looking GuidanceTransEnterix, Inc. announced that given the continued uncertainty that exists within the global healthcare market, company cannot currently predict the specific extent or duration of the impact of the COVID-19 pandemic on financial and operating results. The company is not providing forward looking guidance at this time.お知らせ • Oct 28TransEnterix, Inc. to Report Q3, 2020 Results on Nov 05, 2020TransEnterix, Inc. announced that they will report Q3, 2020 results on Nov 05, 2020お知らせ • Oct 14TransEnterix, Inc. Announces First Pediatric Surgical Cases with Senhance® Surgical SystemTransEnterix, Inc. announced that surgeons at Maastricht University Medical Center+ (MUMC+) in the Netherlands, have successfully operated on multiple pediatric patients, becoming the first pediatric surgical program in the world to utilize the Senhance® Surgical System and integrate digital laparoscopy with instruments as small as 3 mm into their standard of surgical care. The SenhanceSurgical System is the first and only digital laparoscopic platform designed to maintain laparoscopic minimally invasive surgery standards while providing digital benefits such as haptic feedback, robotic precision, eye-sensing camera control, comfortable ergonomics, advanced instrumentation including 3 mm microlaparoscopic instruments, and reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.お知らせ • Oct 08TransEnterix Announces Toshima Hospital in Japan to Initiate A Senhance® Digital Laparoscopy ProgramTransEnterix, Inc. announced that the Toshima Hospital of the Tokyo Metropolitan Health and Hospitals Corporation has entered into an agreement to lease and utilize a Senhance® Surgical System. Toshima Hospital is a comprehensive inpatient and outpatient facility with 415 inpatient beds, and is affiliated with the Tokyo Medical and Dental University. The hospital is part of the six hospital network operated by the Tokyo Metropolitan Health and Hospitals Corporation to provide excellence in healthcare and promote the welfare of the citizens of the Tokyo metro area. The Senhance Surgical System is the first and only digital laparoscopic platform designed to maintain laparoscopic minimally invasive surgical standards while providing digital benefits such as haptic feedback, robotic precision, eye-sensing camera control, comfortable ergonomics, advanced instrumentation including, 3 mm microlaparoscopic instruments, and reusable standard instruments to help maintaining per-procedure costs similar to traditional laparoscopy. The Senhance Surgical System was approved for use by the Japanese Ministry of Health, Labor and Welfare (MHLW) in 2019, and has the broadest procedural reimbursement of any abdominal robotic surgery platform in Japan, which applies to 98 benign and malignant laparoscopic procedures across general, colorectal, gynecologic, pediatric and urologic surgeries at reimbursement rates equivalent to traditional laparoscopy in Category A1.お知らせ • Aug 23Transenterix, Inc. Not Provide Revenue GuidanceTransEnterix, Inc. announced that given the continued uncertainty that exists within the global healthcare market, the company cannot currently predict the specific extent or duration of the impact of the COVID-19 outbreak on its financial and operating results. As a result, the company is not providing forward looking revenue guidance at this time.お知らせ • Aug 06TransEnterix, Inc. Contemplates BankruptcyTransEnterix, Inc. is contemplating filing for bankruptcy, as of August 5, 2020. According to SEC filing, the ability of the company to continue as a going concern is dependent on the company obtaining adequate capital to fund operating losses until it becomes profitable. Management's plan to obtain additional resources for the company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights. If such sufficient funds are not received on a timely basis, the company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection.お知らせ • Jul 23TransEnterix, Inc. to Report Q2, 2020 Results on Aug 05, 2020TransEnterix, Inc. announced that they will report Q2, 2020 results on Aug 05, 2020お知らせ • Jul 05TransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Growth IndexTransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Growth Indexお知らせ • Jul 04TransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2000 Dynamic IndexTransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2000 Dynamic Indexお知らせ • Jul 03+ 2 more updatesTransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Value IndexTransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Value Indexお知らせ • Jul 02+ 3 more updatesTransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2500 Growth IndexTransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2500 Growth Indexお知らせ • Jun 22TransEnterix, Inc.(AMEX:TRXC) dropped from S&P Global BMI IndexTransEnterix, Inc.(AMEX:TRXC) dropped from S&P Global BMI Index株主還元ASXCUS Medical EquipmentUS 市場7D21.9%4.4%1.0%1Y23.5%-17.9%28.7%株主還元を見る業界別リターン: ASXC過去 1 年間で-17.9 % の収益を上げたUS Medical Equipment業界を上回りました。リターン対市場: ASXCは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is ASXC's price volatile compared to industry and market?ASXC volatilityASXC Average Weekly Movement13.4%Medical Equipment Industry Average Movement8.7%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: ASXCの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ASXCの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a208Anthony Fernandowww.asensus.com医療機器メーカーであるアセンサス・サージカル社は、米国、欧州、中東、アフリカ、アジアにおいて、低侵襲手術（MIS）を強化する医療機器ロボットの研究、開発、販売を行っている。外科医と患者間のインターフェイスをデジタル化し、外科医が患者に成果をもたらすためのパフォーマンスガイド付き手術を行う。同社の製品には、最大4本のアームでロボット器具と腹腔鏡手術用カメラを制御できるマルチポートロボット手術システムであるSenhanceシステム、直径3mmの器具、3mmと5mmのフック、関節器具を含む器具やその他の製品、組織を結紮・分割するために制御されたエネルギーを供給する高度なエネルギー装置であるSenhance超音波システムなどがある。同社は以前はトランスエンテリックス社として知られていたが、2021年2月に社名をアセンサスサージカル社に変更した。本社はノースカロライナ州ダーラム。もっと見るAsensus Surgical, Inc. 基礎のまとめAsensus Surgical の収益と売上を時価総額と比較するとどうか。ASXC 基礎統計学時価総額US$94.92m収益（TTM）-US$83.80m売上高(TTM)US$9.85m9.6xP/Sレシオ-1.1xPER（株価収益率ASXC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ASXC 損益計算書（TTM）収益US$9.85m売上原価US$12.85m売上総利益-US$3.00mその他の費用US$80.80m収益-US$83.80m直近の収益報告Jun 30, 2024次回決算日該当なし一株当たり利益（EPS）-0.31グロス・マージン-30.45%純利益率-850.75%有利子負債／自己資本比率0%ASXC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/08/22 12:07終値2024/08/22 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Asensus Surgical, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Gregory ChodaczekB. Riley Securities, Inc.Sean LavinBTIGRoss OsbornCantor Fitzgerald & Co.7 その他のアナリストを表示
お知らせ • Aug 23+ 2 more updatesAsensus Surgical, Inc.(NYSEAM:ASXC) dropped from S&P TMI IndexAsensus Surgical, Inc.(NYSEAM:ASXC) dropped from S&P TMI Index
New Risk • Aug 15New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$11m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$57m free cash flow). Negative equity (-US$11m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$8.4m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Market cap is less than US$100m (US$76.3m market cap).
お知らせ • Aug 08Asensus Surgical, Inc. to Report Q2, 2024 Results on Aug 13, 2024Asensus Surgical, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024
お知らせ • Jul 23Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in UrologyAsensus Surgical, Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration or an expanded indication to treat adult and pediatric Urology patients with the Senhance® Surgical System. Healthcare providers perform upwards of 185,000 urological surgical procedures each year in the United States. While the Senhance System has been successfully utilized for Urology procedures outside the U.S. for several years, this expanded indication will open the door to this important specialty to leverage the advantages of the Senhance System in the U.S. patient population. The Senhance Surgical System is designed to increase surgeon control and reduce variability through Augmented Intelligence and deep learning capabilities.
New Risk • Jun 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$61m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (US$63.9m market cap).
Reported Earnings • May 16First quarter 2024 earnings: EPS and revenues miss analyst expectationsFirst quarter 2024 results: US$83.55 loss per share (further deteriorated from US$0.093 loss in 1Q 2023). Revenue: US$1.12m (up 15% from 1Q 2023). Net loss: US$22.5m (loss widened 1.3% from 1Q 2023). Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) also missed analyst estimates by 60%. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
お知らせ • Aug 23+ 2 more updatesAsensus Surgical, Inc.(NYSEAM:ASXC) dropped from S&P TMI IndexAsensus Surgical, Inc.(NYSEAM:ASXC) dropped from S&P TMI Index
New Risk • Aug 15New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$11m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$57m free cash flow). Negative equity (-US$11m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$8.4m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Market cap is less than US$100m (US$76.3m market cap).
お知らせ • Aug 08Asensus Surgical, Inc. to Report Q2, 2024 Results on Aug 13, 2024Asensus Surgical, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024
お知らせ • Jul 23Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in UrologyAsensus Surgical, Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration or an expanded indication to treat adult and pediatric Urology patients with the Senhance® Surgical System. Healthcare providers perform upwards of 185,000 urological surgical procedures each year in the United States. While the Senhance System has been successfully utilized for Urology procedures outside the U.S. for several years, this expanded indication will open the door to this important specialty to leverage the advantages of the Senhance System in the U.S. patient population. The Senhance Surgical System is designed to increase surgeon control and reduce variability through Augmented Intelligence and deep learning capabilities.
New Risk • Jun 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$61m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (US$63.9m market cap).
Reported Earnings • May 16First quarter 2024 earnings: EPS and revenues miss analyst expectationsFirst quarter 2024 results: US$83.55 loss per share (further deteriorated from US$0.093 loss in 1Q 2023). Revenue: US$1.12m (up 15% from 1Q 2023). Net loss: US$22.5m (loss widened 1.3% from 1Q 2023). Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) also missed analyst estimates by 60%. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
Major Estimate Revision • May 16Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$12.3m to US$9.80m. Forecast losses increased from -US$0.185 to -US$0.27 per share. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$0.35 unchanged from last update. Share price was steady at US$0.26 over the past week.
お知らせ • May 09Asensus Surgical, Inc. to Report Q1, 2024 Results on May 14, 2024Asensus Surgical, Inc. announced that they will report Q1, 2024 results After-Market on May 14, 2024
New Risk • Apr 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$64m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$24m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (US$77.5m market cap).
お知らせ • Apr 04KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million.KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million on March 28, 2024. As part of consideration, KARL STORZ SE & Co. will pay $0.35 in cash for each share of Asensus Surgical. If the proposed transaction is consummated, Asensus will cease to be a publicly traded company. The Bridge Loan will enable Asensus to receive a loan of up to $20 million from KARL STORZ to support the Company’s operations through the exclusivity period. The transaction is subject to, among other conditions, completion of due diligence by KARL STORZ, negotiation of a definitive merger agreement, a recommendation by the Transaction Committee and approval by the Board of Directors and stockholders of Asensus Surgical, and other customary closing conditions to be included in the definitive merger agreement, if any. If negotiations are terminated during the exclusivity period, or, if entered into, the definitive merger agreement is terminated, KARL STORZ will cease to provide any additional bridge financing and the Asensus Surgical will be required to repay the Bridge Loan to KARL STORZ within a prescribed period. Jefferies LLC acted as financial advisor to Asensus Surgical.
Reported Earnings • Mar 22Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: US$0.31 loss per share. Revenue: US$8.58m (up 21% from FY 2022). Net loss: US$78.4m (loss widened 3.8% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.6%. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.
お知らせ • Mar 16Asensus Surgical, Inc. to Report Q4, 2023 Results on Mar 21, 2024Asensus Surgical, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Mar 21, 2024
Recent Insider Transactions Derivative • Feb 07President exercised options and sold US$131k worth of stockOn the 4th of February, Anthony Fernando exercised options to acquire 485k shares at no cost and sold these for an average price of US$0.27 per share. This trade did not impact their existing holding. For the year to December 2017, Anthony's total compensation was 18% salary and 82% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2023, Anthony has owned 1.49m shares directly. Company insiders have collectively bought US$38k more than they sold, via options and on-market transactions, in the last 12 months.
Major Estimate Revision • Jan 20Consensus revenue estimates increase by 10%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$7.79m to US$8.59m. EPS estimate unchanged from -US$0.32 at last update. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target of US$2.00 unchanged from last update. Share price fell 9.9% to US$0.29 over the past week.
お知らせ • Jan 08Asensus Surgical, Inc. Provides Unaudited Earnings Guidance for the Quarter and Full Year Ending on December 31, 2023Asensus Surgical, Inc. provided unaudited guidance For the quarter and full year ending on December 31, 2023. For the quarter, the company estimates preliminary unaudited revenue of approximately $5.1- $5.7 million. For the full year, preliminary unaudited 2023 revenue is expected to be approximately $8.2 - $8.8 million, representing revenues from the sale of three Senhance Systems, multiple system leases, and related revenues from instruments, accessories, and services.
お知らせ • Jan 05Asensus Surgical, Inc. Develops the LUNA Surgical SystemAsensus Surgical, Inc. announced a key development milestone for LUNA, the Company’s second-generation surgical robotic system. During the week of December 11, 2023, the Company hosted a Surgeon Lab in Research Triangle Park, North Carolina to conduct an in vivo evaluation of LUNA’s hardware, software and instruments in porcine models. The lab allowed nine participating surgeons to evaluate the system's functionality through thirteen different procedures across gynecology, urology, and general surgery. LUNA, the Company’s Next Generation Digital Surgery Platform: LUNA is designed to elevate the standards of robotic-assisted surgery. The system integrates carefully crafted hardware and software architecture to prioritize safety, reliability, and performance. LUNA's features include a surgeon console with unconstrained handles, an interactive touchscreen, and an Ultra-HD 3D monitor. Additionally, the system boasts up to four independent robotic manipulator arms for procedural flexibility, alongside a unique instrument drive system supporting various advanced instrumentation options. LUNA is currently under development and has not been submitted to, or cleared by, the US FDA or other global regulators, and is not available for sale in any market.
Reported Earnings • Nov 17Third quarter 2023 earnings: EPS in line with expectations, revenues disappointThird quarter 2023 results: US$0.072 loss per share (improved from US$0.08 loss in 3Q 2022). Revenue: US$1.09m (down 57% from 3Q 2022). Net loss: US$18.3m (loss narrowed 3.2% from 3Q 2022). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
お知らせ • Nov 08Asensus Surgical, Inc. to Report Q3, 2023 Results on Nov 14, 2023Asensus Surgical, Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023
Reported Earnings • Aug 11Second quarter 2023 earnings: EPS misses analyst expectationsSecond quarter 2023 results: US$0.086 loss per share (further deteriorated from US$0.083 loss in 2Q 2022). Revenue: US$1.08m (up 8.8% from 2Q 2022). Net loss: US$20.7m (loss widened 5.3% from 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Aug 03Asensus Surgical, Inc. to Report Q2, 2023 Results on Aug 10, 2023Asensus Surgical, Inc. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023
New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$61m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$41m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$71.8m market cap).
Major Estimate Revision • May 18Consensus EPS estimates fall by 23%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.26 to -US$0.32 per share. Revenue forecast of US$8.67m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target of US$1.65 unchanged from last update. Share price fell 15% to US$0.58 over the past week.
Reported Earnings • May 13First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.093 loss per share (further deteriorated from US$0.081 loss in 1Q 2022). Net loss: US$22.2m (loss widened 16% from 1Q 2022). Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 116% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Major Estimate Revision • Mar 09Consensus revenue estimates fall by 34%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$17.0m to US$11.2m. Forecast losses increased from -US$0.25 to -US$0.26 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$2.25 to US$1.75. Share price fell 2.3% to US$0.67 over the past week.
Price Target Changed • Mar 06Price target decreased by 21% to US$1.75Down from US$2.22, the current price target is an average from 2 analysts. New target price is 159% above last closing price of US$0.68. Stock is up 9.5% over the past year. The company is forecast to post a net loss per share of US$0.26 next year compared to a net loss per share of US$0.32 last year.
Reported Earnings • Mar 03Full year 2022 earnings: EPS exceeds analyst expectationsFull year 2022 results: US$0.32 loss per share (further deteriorated from US$0.28 loss in FY 2021). Net loss: US$75.6m (loss widened 21% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.9%. Revenue is forecast to grow 69% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions Derivative • Feb 08President exercised options and sold US$406k worth of stockOn the 4th of February, Anthony Fernando exercised options to acquire 542k shares at no cost and sold these for an average price of US$0.75 per share. This trade did not impact their existing holding. For the year to December 2016, Anthony's total compensation was 6% salary and 94% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2022, Anthony has owned 823.12k shares directly. Company insiders have collectively sold US$253k more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Jan 10Asensus Surgical, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022Asensus Surgical, Inc. provided unaudited revenue guidance for the Fourth quarter and Full year 2022. For the quarter, the company expected unaudited revenue is to be approximately $2.2 million - $2.8 million. For the year, the company expected unaudited revenue is to be approximately $6.8 million - $7.4 million.
Board Change • Dec 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. President, CEO & Director Anthony Fernando was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Major Estimate Revision • Nov 17Consensus revenue estimates fall by 17%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$9.15m to US$7.60m. Forecast losses increased from -US$0.31 to -US$0.32 per share. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$2.25 unchanged from last update. Share price rose 8.3% to US$0.44 over the past week.
Reported Earnings • Nov 16Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.08 loss per share (further deteriorated from US$0.069 loss in 3Q 2021). Net loss: US$18.9m (loss widened 18% from 3Q 2021). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 12Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.08 loss per share (further deteriorated from US$0.069 loss in 3Q 2021). Net loss: US$18.9m (loss widened 18% from 3Q 2021). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
Price Target Changed • Nov 05Price target decreased to US$2.25Down from US$4.00, the current price target is an average from 2 analysts. New target price is 456% above last closing price of US$0.41. Stock is down 81% over the past year. The company is forecast to post a net loss per share of US$0.31 next year compared to a net loss per share of US$0.28 last year.
お知らせ • Nov 01Asensus Surgical, Inc. to Report Q3, 2022 Results on Nov 10, 2022Asensus Surgical, Inc. announced that they will report Q3, 2022 results After-Market on Nov 10, 2022
お知らせ • Aug 10Asensus Surgical, Inc. Announces Impairment Charges for Three Months Ended June 30, 2022Asensus Surgical, Inc. announced impairment charges for three months Ended June 30, 2022. For the period, the company announced Property and equipment impairment of $432,000.
お知らせ • Jul 28Asensus Surgical, Inc. to Report Q2, 2022 Results on Aug 08, 2022Asensus Surgical, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2022
お知らせ • Jun 29Asensus Surgical, Inc. to Showcase the Senhance Surgical System and Performance-Guided Surgery in Upcoming Society of Robotic and Digital Surgery ConferenceAsensus Surgical, Inc. announced the will be participating in the Society of Robotic and Digital Surgery Conference from June 30, 2022 until July 3, 2022 in Lake Buena Vista, Florida. Asensus Surgical's technology platform, Senhance® Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit (ISU™). The ISU enables machine vision-driven tools to gather data related to anatomical structures and control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field and allows a surgeon to change the visualized field of view using the movement of their instruments. As an organization, the Company’s goal is to revolutionize the way surgery is performed. The Company is helping to unlock clinical intelligence and capabilities to reduce surgical variability and the complications associated with it. Performance-Guided Surgery builds upon the foundation of Digital Laparoscopy by adding machine vision, augmented intelligence, and deep learning capabilities, and will be built upon the digital library of data collected from surgeries performed using Senhance. The insights gained from these cases will help deliver on the promise of consistently superior surgery regardless of a surgeon’s experience or skill level by guiding improved decision making, enriching collaboration, and enhancing predictability.
お知らせ • Apr 26Asensus Surgical, Inc., Annual General Meeting, Jun 14, 2022Asensus Surgical, Inc., Annual General Meeting, Jun 14, 2022, at 11:00 US Eastern Standard Time. Agenda: To consider the election of the seven director nominees named in the attached proxy statement to serve as directors until the next annual meeting of stockholders and until their successors are elected and qualified; to consider an advisory vote to approve the compensation paid to the Company’s named executive officers for 2021; to consider ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022; and to consider the transaction of such other business as may lawfully come before the Annual Meeting or at any adjournment or postponement.
お知らせ • Feb 24Asensus Surgical, Inc. to Report Q4, 2021 Results on Feb 28, 2022Asensus Surgical, Inc. announced that they will report Q4, 2021 results After-Market on Feb 28, 2022
お知らせ • Sep 29Asensus Surgical, Inc. Announces Purchase of Senhance Robotic System by Loginov Moscow Clinical Scientific CenterAsensus Surgical, Inc. announced that Loginov Moscow Clinical Scientific Center, located in Moscow, Russia, has initiated its Senhance® Robotic Surgery program following the purchase of a Senhance Surgical System. The installation represents the first Senhance Surgical System to be used within Russia. Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3 mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit™ (ISU™). The ISU enables machine vision-driven control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field, and allows a surgeon to change the visualized field of view using the movement of their instruments. The newest ISU features expand upon these capabilities and introduce more advanced features including: 3D measurement, digital tagging, image enhancement, and enhanced camera control based on real-time data from anatomical structures while performing surgery. The Loginov Moscow Clinical Scientific Center (The Loginov MCSC) is one of the and most innovative institutions funded by the Moscow Health Department. The Loginov MCSC is a multi-disciplinary clinical, research, and training center hosting 48 medical departments, employing around 500 doctors, and performing more than 13,000 annual operations. The Loginov MCSC is headed by Professor Igor Khatkov, a proponent of minimally invasive surgical technologies and a world leader in laparoscopic pancreatic surgery. Since its founding in July 2013, The Loginov MCSC has spent considerable resources on educational activities. The training center trains specialists in 12 medical specialties in residency and four specialties in fellowship. The center features a program for the development of robotic surgery, headed by Professor Nikolay Matveev, carried out in cooperation with the Department of Surgery of the Biomedical Faculty, Pirogov Russian National Research Medical University.
お知らせ • Sep 02Asensus Surgical Receives FDA 510(k) Clearance for Expansion of Machine Vision CapabilitiesAsensus Surgical, Inc. announced that it has received 510(k) clearance from the FDA for an expansion of machine vision capabilities on the previously cleared Intelligent Surgical Unit™ (ISU™). The ISU is utilized with the Company’s Senhance Surgical System which enables Digital Laparoscopy. The current features of the ISU enable machine vision-driven control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field, and allow a surgeon to change the visualized field of view using the movement of their instruments. The newest ISU features expand upon these capabilities and introduce more advanced features including: 3D measurement, digital tagging, image enhancement, and enhanced camera control based on real-time data from anatomical structures while performing surgery. This will be the first time any of these features will be clinically available in soft-tissue abdominal surgery. The 3D measurement feature enables the surgeon to use their instruments to designate points on the tissue floor to determine both straight-line distances as well as true topographic distances over the folds and recesses of the abdominal cavity. In traditional minimally invasive surgery, such measurements are estimated or require the use of a sterile measuring tape inside the abdominal cavity. Now 3D measurement allows for accurate readings to millimeter-level accuracy that can assist in various surgical tasks, such as the sizing of hernia mesh or the planning of a staple line. These measurement capabilities represent the first time surgeons have the ability to acquire accurate, real-time measurements without the need for additional tools.
お知らせ • May 15Asensus Surgical, Inc. Expects to File for FDA 510(K) Clearance for the Next Wave of ISU Features During the Second Quarter of 2021 and Expects to Publish Clinical Papers in Peer Reviewed Journals on Health Economic Evidence Comparing Senhance, Robotics and Laparoscopy in General Surgery and GynecologyAsensus Surgical, Inc. announced that during the second quarter of 2021, the Company expects to achieve the following regulatory milestones: File for FDA 510(k) clearance for the next wave of ISU features. During the second half of 2021, the Company expects to publish clinical papers in peer reviewed journals on the following subjects: Health economic evidence comparing Senhance, robotics and laparoscopy in General Surgery and Gynecology.
お知らせ • Mar 05Asensus Surgical, Inc. to Report Q4, 2020 Results on Mar 11, 2021Asensus Surgical, Inc. announced that they will report Q4, 2020 results After-Market on Mar 11, 2021
お知らせ • Mar 04Asensus Surgical Announces FDA Clearance in General SurgeryAsensus Surgical, Inc. announced the company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States. Asensus Surgical's technology platform, Senhance® Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3 mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is intended to assist in the accurate control of laparoscopic instruments for visualization and endoscopic manipulation of tissue including grasping, cutting, blunt and sharp dissection, approximation, ligation, electrocautery, suturing, mobilization, and retraction. The Senhance Surgical System is intended for use in general laparoscopic surgical procedures and laparoscopic gynecological surgery. The system is indicated for adult use. It is intended for use by trained physicians in an operating room environment in accordance with the instructions for use.
お知らせ • Jan 29TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $69.249999 million.TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $69.249999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 23,083,333 Price\Range: $3 Discount Per Security: $0.225
お知らせ • Jan 15TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $31.25 million.TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $31.25 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: $1.25 Discount Per Security: $0.096875 Transaction Features: Registered Direct Offering
お知らせ • Dec 19TransEnterix, Inc. Announces Southern Surgical Hospital to Initiate a Senhance Digital Laparoscopic ProgramTransEnterix, Inc. announced that Southern Surgical Hospital has entered into an agreement to lease and utilize a Senhance Surgical System. The Senhance System is the first new abdominal robotic surgery platform to receive FDA clearance since 2000. It is the first and only digital laparoscopic surgical platform designed to maintain laparoscopic minimally invasive surgical standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including 3 mm microlaparoscopic instruments, eye-sensing camera control, and reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy. TransEnterix recently launched the first machine vision system in robotic surgery. This first-of-its-kind augmented intelligence capability is powered by the new Intelligent Surgical Unit on the Senhance Surgical System.
お知らせ • Dec 18TransEnterix Announces Approval of Senhance Surgical System in Russian FederationTransEnterix, Inc. announced that the Senhance® Surgical System has received its registration certificate by Roszdravnadzor, the Russian medical device regulatory agency allowing for its sale and utilization throughout the Russian Federation.
お知らせ • Nov 06+ 1 more updateTransenterix, Inc. Does Not Provide Forward-Looking GuidanceTransEnterix, Inc. announced that given the continued uncertainty that exists within the global healthcare market, company cannot currently predict the specific extent or duration of the impact of the COVID-19 pandemic on financial and operating results. The company is not providing forward looking guidance at this time.
お知らせ • Oct 28TransEnterix, Inc. to Report Q3, 2020 Results on Nov 05, 2020TransEnterix, Inc. announced that they will report Q3, 2020 results on Nov 05, 2020
お知らせ • Oct 14TransEnterix, Inc. Announces First Pediatric Surgical Cases with Senhance® Surgical SystemTransEnterix, Inc. announced that surgeons at Maastricht University Medical Center+ (MUMC+) in the Netherlands, have successfully operated on multiple pediatric patients, becoming the first pediatric surgical program in the world to utilize the Senhance® Surgical System and integrate digital laparoscopy with instruments as small as 3 mm into their standard of surgical care. The SenhanceSurgical System is the first and only digital laparoscopic platform designed to maintain laparoscopic minimally invasive surgery standards while providing digital benefits such as haptic feedback, robotic precision, eye-sensing camera control, comfortable ergonomics, advanced instrumentation including 3 mm microlaparoscopic instruments, and reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.
お知らせ • Oct 08TransEnterix Announces Toshima Hospital in Japan to Initiate A Senhance® Digital Laparoscopy ProgramTransEnterix, Inc. announced that the Toshima Hospital of the Tokyo Metropolitan Health and Hospitals Corporation has entered into an agreement to lease and utilize a Senhance® Surgical System. Toshima Hospital is a comprehensive inpatient and outpatient facility with 415 inpatient beds, and is affiliated with the Tokyo Medical and Dental University. The hospital is part of the six hospital network operated by the Tokyo Metropolitan Health and Hospitals Corporation to provide excellence in healthcare and promote the welfare of the citizens of the Tokyo metro area. The Senhance Surgical System is the first and only digital laparoscopic platform designed to maintain laparoscopic minimally invasive surgical standards while providing digital benefits such as haptic feedback, robotic precision, eye-sensing camera control, comfortable ergonomics, advanced instrumentation including, 3 mm microlaparoscopic instruments, and reusable standard instruments to help maintaining per-procedure costs similar to traditional laparoscopy. The Senhance Surgical System was approved for use by the Japanese Ministry of Health, Labor and Welfare (MHLW) in 2019, and has the broadest procedural reimbursement of any abdominal robotic surgery platform in Japan, which applies to 98 benign and malignant laparoscopic procedures across general, colorectal, gynecologic, pediatric and urologic surgeries at reimbursement rates equivalent to traditional laparoscopy in Category A1.
お知らせ • Aug 23Transenterix, Inc. Not Provide Revenue GuidanceTransEnterix, Inc. announced that given the continued uncertainty that exists within the global healthcare market, the company cannot currently predict the specific extent or duration of the impact of the COVID-19 outbreak on its financial and operating results. As a result, the company is not providing forward looking revenue guidance at this time.
お知らせ • Aug 06TransEnterix, Inc. Contemplates BankruptcyTransEnterix, Inc. is contemplating filing for bankruptcy, as of August 5, 2020. According to SEC filing, the ability of the company to continue as a going concern is dependent on the company obtaining adequate capital to fund operating losses until it becomes profitable. Management's plan to obtain additional resources for the company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights. If such sufficient funds are not received on a timely basis, the company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection.
お知らせ • Jul 23TransEnterix, Inc. to Report Q2, 2020 Results on Aug 05, 2020TransEnterix, Inc. announced that they will report Q2, 2020 results on Aug 05, 2020
お知らせ • Jul 05TransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Growth IndexTransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Growth Index
お知らせ • Jul 04TransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2000 Dynamic IndexTransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2000 Dynamic Index
お知らせ • Jul 03+ 2 more updatesTransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Value IndexTransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Value Index
お知らせ • Jul 02+ 3 more updatesTransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2500 Growth IndexTransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2500 Growth Index
お知らせ • Jun 22TransEnterix, Inc.(AMEX:TRXC) dropped from S&P Global BMI IndexTransEnterix, Inc.(AMEX:TRXC) dropped from S&P Global BMI Index
